Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1131Triple Negative Breast Neoplasms 147Neoplasm Metastasis 99Carcinoma, Non-Small-Cell Lung 85Ovarian Neoplasms 81Neoplasms 75Lung Neoplasms 64Colorectal Neoplasms 60Melanoma 59Stomach Neoplasms 44Pancreatic Neoplasms 43Breast Neoplasms, Male 43Prostatic Neoplasms 42Carcinoma, Renal Cell 37Squamous Cell Carcinoma of Head and Neck 34Sarcoma 30Colonic Neoplasms 29Endometrial Neoplasms 28Head and Neck Neoplasms 26Brain Neoplasms 24Urinary Bladder Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 21Carcinoma, Intraductal, Noninfiltrating 21Lymphoma, Non-Hodgkin 19Recurrence 18Uterine Cervical Neoplasms 17Inflammatory Breast Neoplasms 17Breast Carcinoma In Situ 17Multiple Myeloma 16

Interventions

abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fibrocystic Breast Disease × Breast × Clear all
NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡